U.S. CENTRAL VENOUS CATHETER MARKET ANALYSIS

Central venous catheters play a major role in modern healthcare. These catheters allow easy administration of intravenous fluids, blood products, medications, and parenteral nutrition, as well as offer hemodialysis access and hemodynamic monitoring. They are used in various diseases for longer duration therapies such as cancer (chemotherapy) and end stage renal disease (dialysis).

U.S. Central Venous Catheter Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. COVID-19 has also affected the economies in three main ways- by directly affecting the production and demand, by creating disruptions in distribution channels, and through its financial impact on companies and financial markets. The increase in central-line–associated bloodstream infections and blood culture contamination rates increase the market growth. For instance, in November 2020, National Center for Biotechnology Information published a report which reported that a there was a significant increase in central-line–associated bloodstream infections and blood culture contamination rates during the pandemic. Blood culture contamination rates were 19% higher during the COVID-19 period, whereas the CLABSI (central-line–associated bloodstream infections) rate during the pandemic increased by 25% in US.

Thus, impact of the Coronavirus (COVID-19) pandemic had driven the growth of the U.S. central venous catheter market during the pandemic.

U.S. central venous catheter market is estimated to be valued at USD 1,142.4 Mn in 2024 and is expected to exhibit a CAGR of 6.2% during the forecast period (2024-2031).

Figure 1. U.S. Central Venous Catheter Market Value (USD Mn), by Product Type, 2024

To learn more about this report, request sample copy

Increasing number of advantages associated with single lumen is expected to drive the growth of U.S. central venous catheter market

Increasing advantages associated with single lumen drives the growth of U.S. central venous catheter market over the forecast period. For example:

• Single lumen are simplest means of lung isolation
• Does not require any special equipment
• Preferred for emergencies such as contralateral tension pneumothorax
• Lower rate of infection associated with single lumen as compared to double and multiple lumen.

U.S. Central Venous Catheter Market – Restraints

There are various restrains associated with central venous catheter market such as:

• Peripherally inserted central catheters requires experienced specialist, need radiological confirmation, requires training of patients for suitable device care.
• Non-tunneled central line have higher risk of being affected by infection, their usage duration is limited and patients cannot be sent home
• Central line midline catheters cannot be used to draw blood; only solutions which are peripherally compatible cannot be applied.

Figure 2. U.S. Central Venous Catheter Market Share, By Design, 2024

To learn more about this report, request sample copy

Recent Developments

In November 2023, CorMedix Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved DefenCath (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in a limited population of adult kidney failure patients receiving chronic hemodialysis via a central venous catheter (CVC).

In June 2023, Merit Medical Systems, Inc., a global medical device manufacturer, announced that it has completed the purchase of Bluegrass Vascular Technologies, Inc.'s Surfacer Inside-Out Access Catheter System for a total cash consideration of USD 32.5 million. The Surfacer System is a life-saving device for hemodialysis patients on catheters, as well as patients with other illnesses requiring venous access, who experience central venous occlusions.

In August 2022, Teleflex Incorporated, a leading global provider of medical technologies, announced that it has been granted a contract by Vizient, Inc., the largest member-driven healthcare performance improvement firm in the U.S., to deliver Central Venous Access products. Vizient Inc. offers solutions and services that improve the delivery of high-value care by harmonizing cost, quality, and market performance for more than half of the country's acute care providers.

Increasing use of peripherally inserted central catheters is expected to bolster the U.S. central venous catheter market growth over the forecast period.

Increasing use of peripherally inserted central catheters associated with low complications is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in May 2021, Journal of Medicine and Life, a peer-reviewed open access journal, published a report which stated that PICCs (peripherally inserted central catheters) may be used as a safe option for central venous access in children either in the intermediate- or long-term. New types of PICC may facilitate broader indications and provide longer dwell times. PICC placement can be learned easily, usually requires light sedation and/or local anesthesia, and seldom causes serious perioperative risks. Application of assisted visualization and having well-educated staff could improve the insertion success rate and reduce the complications of PICCs.

U.S. Central Venous Catheter Market - Competitive Landscape

Key players operating in the global osteoporosis drugs market include AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL,  Gilead Sciences, Inc and ZOLL Medical Corporation